NFE2L2 and lung cancer: For the 330 patients with advanced KRAS-mutant lung cancer screened, the most common co-occurring genomic alterations were TP53 (42%), STK11 (29%), and KEAP1/NFE2L2 (27%), and KEAP1/NFE2L2 co-mutation was an independent prognostic factor that predicted shorter survival [19].